Key Points - Robbins LLP has filed a securities class action on behalf of Capricor Therapeutics, Inc. investors. - Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to lead the class action lawsuit. - The U.S. FDA's review extension of Capricor's Biologics License Application has...
Key Points - Rosen Law Firm sets lead plaintiff deadline of October 27, 2026 for Hyliion...
Vaxart, Inc. (VXRT) shares are trading higher Thursday, a move worth watching in the Healthcare space.The...
Ocular Therapeutix, Inc. (OCUL) gives both camps something to hold. These are the 8 bullish and...
Every position is an argument with someone on the other side. Here is what the numbers...
from Lake Street issued a price target of $10.00 for LTRX on 2026-09-18 12:51:41.The adjusted price target was set to $10.00.At the time of the announcement, LTRX was trading at...
from Lake Street issued a price target of $149.00 for SPRB on 2026-09-17 11:45:50.The adjusted price target was set to $149.00.At the time of the announcement, SPRB was trading at...
from Craig-Hallum issued a price target of $40.00 for PRE on 2026-09-17 11:13:33.The adjusted price target was set to $40.00.At the time of the announcement, PRE was trading at $22.02.The...
from Oppenheimer issued a price target of $7.00 for KOPN on 2026-09-17 10:40:40.The adjusted price target was set to $7.00.At the time of the announcement, KOPN was trading at $4.34.The...
Alexander Sklar from Raymond James issued a price target of $90.00 for RDVT on 2026-09-17 10:05:00.The adjusted price target was set to $90.00.At the time of the announcement, RDVT was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
